Chronological reference of FDA actions and major court rulings affecting compounded semaglutide and tirzepatide from the start of the GLP-1 shortages (2022) through April 2026. Each event has its own permalink anchor and is sourced to FDA documents, court filings, or contemporaneous coverage.
FDA GLP-1 enforcement at a glance: shortage windows + key events
The visual at a glance: semaglutide and tirzepatide shortage periods (yellow) overlap with 503A/503B compounding-allowed windows (green); the windows close at the FDA enforcement deadlines (April 28 and May 22, 2025). Key event markers below.
Timeline
Reverse-chronological is below the primary chronological order; bookmark and link to specific events using the anchor URL on each card.
2022-08 (semaglutide)
FDA actionFDA places semaglutide injection on the drug shortage list
FDA’s Drug Shortages Database lists semaglutide injection (Wegovy, Ozempic) due to demand exceeding manufacturer supply. The shortage status enables compounding pharmacies under FD&C Act § 503A and § 503B to legally produce semaglutide for patient use.
2022-12 (tirzepatide)
FDA actionFDA places tirzepatide injection on the drug shortage list
Tirzepatide (Mounjaro) added to the FDA shortage list as demand outpaced supply post-launch. Like semaglutide, this enabled legal compounding under § 503A and § 503B during the shortage window.
2023
FDA actionFDA adds BPC-157 to “bulk drug substances” safety-concern list
FDA’s “Category 2” interim list of bulk drug substances raising safety concerns added BPC-157, restricting its compounding under § 503A pathways. Not a GLP-1 directly but a peptide-class enforcement signal during the same period.
2023-2024 (Novo Nordisk litigation)
Manufacturer actionNovo Nordisk files lawsuits against compounding pharmacies and med spas marketing “compounded semaglutide”
Novo Nordisk pursued multiple legal actions against pharmacies and medical practices marketing compounded semaglutide as equivalent to FDA-approved Wegovy/Ozempic, alleging trademark infringement, false advertising, and unfair competition. Cases targeted clinics in Texas, California, and elsewhere.
2024-03-08
FDA actionFDA approves Wegovy for cardiovascular risk reduction
FDA expands Wegovy’s label to reduce risk of major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke) in adults with established cardiovascular disease and BMI ≥27, based on the SELECT trial. First obesity drug with a CV outcomes indication.
2024-Q2
Market eventEli Lilly launches LillyDirect, including Zepbound vials at $349-$599/month cash price
LillyDirect’s direct-to-consumer Zepbound vial program offers cash-paying patients $349 (2.5 mg), $499 (5 mg), and $599 (7.5+ mg) per month — substantially below the $1,059 list price for autoinjector pens. The program functions as Lilly’s competitive response to compounded semaglutide pricing.
2024-10-02
FDA actionFDA declares the tirzepatide shortage resolved
FDA’s Drug Shortages Database removes tirzepatide from active shortage status, citing Lilly’s expanded production capacity. This signals the legal basis for compounded tirzepatide is ending. Compounders had relied on the shortage status under § 503A and § 503B.
2024-10
Court rulingOutsourcing Facilities Association sues FDA over tirzepatide shortage delisting
The Outsourcing Facilities Association (OFA) filed suit against FDA seeking to reverse the tirzepatide shortage delisting, arguing that supply remained inadequate to meet patient demand. The case became a key venue for the broader compounded-GLP-1 enforcement question.
2024-12-19
FDA actionFDA reaffirms tirzepatide shortage as resolved after litigation review
After litigation, FDA reaffirms that the tirzepatide shortage is resolved as of October 2, 2024. The agency announces enforcement discretion timelines for 503A and 503B compounders to wind down tirzepatide compounding.
2024-12-20
FDA actionFDA approves Zepbound for moderate-to-severe obstructive sleep apnea
First medication approved for obstructive sleep apnea (OSA) in adults with obesity, based on the SURMOUNT-OSA trial. Zepbound becomes the first drug to address OSA pharmacologically — previous standard was CPAP and weight loss only.
2025-02-21
FDA actionFDA formally declares the semaglutide shortage resolved
FDA’s February 21, 2025 announcement formally ends the semaglutide drug shortage, citing Novo Nordisk’s expanded supply. The agency simultaneously sets enforcement-discretion deadlines for 503A and 503B compounders to wind down semaglutide compounding (April 28 and May 22, 2025 respectively).
2025-Q1
Manufacturer actionMajor telehealth platforms (Hims, Found, Ro) pivot from compounded to branded GLP-1
In response to the FDA’s enforcement timeline, major telehealth providers — including Hims & Hers, Ro (Roman/Rory), Found, and WeightWatchers Clinic — transition their primary GLP-1 offering from compounded semaglutide to branded Wegovy/Ozempic via partnerships with Novo Nordisk and pharmacy networks.
2025-04-28
FDA action503A compounding pharmacy enforcement deadline (semaglutide)
FDA enforcement discretion ends for 503A compounding pharmacies producing semaglutide. After this date, 503A pharmacies must stop mass-compounding semaglutide; only individualized patient-specific compounding (with documented clinical justification per § 503A) remains legal.
2025-04
Manufacturer actionNovo Nordisk and Hims & Hers announce branded Wegovy partnership
Novo Nordisk and Hims & Hers announced a deal to make branded Wegovy available through Hims’s telehealth platform at a discount, marketed as a transition from Hims’s compounded semaglutide offering. The partnership is later terminated in June 2025 after disputes over Hims’s marketing of compounded products in parallel.
2025-05-22
FDA action503B outsourcing facility enforcement deadline (semaglutide)
FDA enforcement discretion ends for 503B outsourcing facilities producing semaglutide. This effectively shut down the large-scale telehealth-compounded semaglutide market that had grown during the 2022-2024 shortage. Many compounding facilities ceased semaglutide production; some continued with what they characterized as patient-specific 503A formulations.
2025-06
Manufacturer actionNovo Nordisk terminates the Hims & Hers Wegovy partnership
Novo Nordisk terminates its partnership with Hims & Hers, citing concerns that Hims continued to market compounded semaglutide alongside or in place of branded Wegovy. The dispute escalates into a broader legal and regulatory tension that contributes to the September 2025 FDA warning letters to Hims.
2025-09-09
FDA actionFDA issues warning letters to Hims & Hers regarding compounded GLP-1 marketing
FDA issues warning letters to Hims and Hers Health on September 9, 2025, citing violations of the Federal Food, Drug, and Cosmetic Act § 502(a) (false or misleading labeling) and § 502(bb) regarding promotion of compounded semaglutide. Specific phrases cited included “Same active ingredient as Ozempic and Wegovy” and “Clinically proven ingredients,” which FDA characterized as misleading drug-equivalence claims.
2026-03 (approx)
Manufacturer actionHims and Novo Nordisk reach a regulatory settlement
Hims & Hers and Novo Nordisk reached a settlement in early 2026 resolving the trademark, false-advertising, and partnership-termination disputes from 2024-2025. Settlement terms reportedly required Hims to cease marketing compounded semaglutide as equivalent to Wegovy or Ozempic and to disclose drug-source distinctions on patient-facing material.
What this timeline tells you about the next 12 months
Three signals from the events above are likely to define 2026-2027:
- 503A personalized compounding remains the only legal compounded-GLP-1 pathway. Pharmacies that pivot to per-patient personalization (e.g., adjusting dose strength to match the prescriber’s clinical judgment) maintain a legal niche. Those that try to mass-produce semaglutide as before are exposed to enforcement.
- The IRA Medicare drug-price negotiation kicks in for Ozempic in 2027. Once the negotiated Maximum Fair Price takes effect, list-price economics shift dramatically. This creates downstream pressure on commercial-insurance pricing too.
- Telehealth providers are now branded-only for the most part. The remaining compounded-GLP-1 telehealth tier is smaller and operates under tighter FDA scrutiny. Branded-GLP-1 telehealth (Found, Ro, WW Clinic, Hims now-branded) is the dominant model.
